Usefulness of the Controlled Attenuation Parameter for Detecting Liver Steatosis in Health Checkup Examinees

Overview

Journal Gut Liver

Specialty Gastroenterology

Date 2015 Feb 27

PMID 25717046

Citations 7

Authors

Ja Kyung Kim

Kwan Sik Lee

Jung Ran Choi

Hyun Jung Chung

Da Hyun Jung

Kyung Ah Lee

Jung Il Lee

Affiliations

Soon will be listed here.

Abstract

Background/aims: The controlled attenuation parameter (CAP) implemented in FibroScan® is reported to be a noninvasive means of detecting steatosis (>10% steatosis). We aimed to evaluate the usefulness of CAP in detecting steatosis among health checkup examinees and to assess its correlation with ultrasonography (US).

Methods: Consecutive CAP results were retrospectively collected. A total of 280 subjects were included.

Results: Fatty liver was detected in 119 subjects (42.5%) by US, whereas it was detected in 160 subjects (57.1%) by the CAP. The numbers of subjects with S0S1S2S3 steatosis according to the CAP value were 120595843, respectively. The mean CAP values were 203.34±28.39 dB/m for S0, 248.83±6.14 dB/m for S1, 274.33±8.53 dB/m for S2, and 322.35±22.20 dB/m for S3. CAP values were correlated with body weight (r=0.404, p<0.001), body mass index (r=0.445, p<0.001), and the fatty liver grade by US (r=0.472, p<0.001). Among the 161 subjects with normal US findings, steatosis was detected in 65 subjects (40.4%) using the CAP.

Conclusions: The CAP seems to be useful for detecting very low-grade hepatic steatosis in health checkup examinees. Its role in predicting subjects with a risk of metabolic derangement needs to be evaluated.

Citing Articles

Effect of essential phospholipids on hepatic steatosis in metabolic dysfunction-associated steatotic liver disease associated with type 2 diabetes mellitus and/or hyperlipidemia and/or obesity: study protocol of a randomized, double-blind, phase IV....

Stefan N, Hartleb M, Popovic B, Varona R Trials. 2024; 25(1):374.

PMID: 38858768 PMC: 11165850. DOI: 10.1186/s13063-024-08208-4.

Liver Involvement in Patients with Systemic Sclerosis: Role of Transient Elastography in the Assessment of Hepatic Fibrosis and Steatosis.

Cuomo G, Iandoli C, Galiero R, Caturano A, Di Vico C, Perretta D Diagnostics (Basel). 2023; 13(10).

PMID: 37238250 PMC: 10217307. DOI: 10.3390/diagnostics13101766.

Validation of Controlled Attenuation Parameter Measured by FibroScan as a Novel Surrogate Marker for the Evaluation of Metabolic Derangement.

Huang Z, Ng K, Chen H, Deng W, Li Y Front Endocrinol (Lausanne). 2022; 12:739875.

PMID: 35173677 PMC: 8841525. DOI: 10.3389/fendo.2021.739875.

Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir.

Kim D, Jeon M, Lee H, Kim B, Park J, Kim D Clin Mol Hepatol. 2018; 25(3):283-293.

PMID: 30419649 PMC: 6759433. DOI: 10.3350/cmh.2018.0054.

Relationship between Serum Cytokeratin-18, Control Attenuation Parameter, NAFLD Fibrosis Score, and Liver Steatosis in Nonalcoholic Fatty Liver Disease.

Kosasih S, Qin W, Rani R, Abd Hamid N, Chai Soon N, Shah S Int J Hepatol. 2018; 2018:9252536.

PMID: 30363686 PMC: 6180970. DOI: 10.1155/2018/9252536.

References

Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati F, Guallar E . Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011; 54(3):1082-1090. PMC: 4197002. DOI: 10.1002/hep.24452. View

Kobayashi J, Murano S, Kawamura I, Nakamura F, Murase Y, Kawashiri M . The relationship of percent body fat by bioelectrical impedance analysis with blood pressure, and glucose and lipid parameters. J Atheroscler Thromb. 2006; 13(5):221-6. DOI: 10.5551/jat.13.221. View

Sasso M, Tengher-Barna I, Ziol M, Miette V, Fournier C, Sandrin L . Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(®): validation in chronic hepatitis C. J Viral Hepat. 2012; 19(4):244-53. DOI: 10.1111/j.1365-2893.2011.01534.x. View

Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G . A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010; 53(2):372-84. DOI: 10.1016/j.jhep.2010.04.008. View

Yun J, Cho Y, Park J, Kim H, Park D, Sohn C . Abnormal glucose tolerance in young male patients with nonalcoholic fatty liver disease. Liver Int. 2009; 29(4):525-9. PMC: 2711255. DOI: 10.1111/j.1478-3231.2008.01920.x. View

Haque M, Sanyal A . The metabolic abnormalities associated with non-alcoholic fatty liver disease. Best Pract Res Clin Gastroenterol. 2002; 16(5):709-31. DOI: 10.1053/bega.2002.0325. View

Kim N, Park J, Kim S, Kim Y, Kim D, Cho G . Non-alcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population. Heart. 2014; 100(12):938-43. DOI: 10.1136/heartjnl-2013-305099. View

Cardi M, Muttillo I, Amadori L, Petroni R, Mingazzini P, Barillari P . Superiority of laparoscopy compared to ultrasonography in diagnosis of widespread liver diseases. Dig Dis Sci. 1997; 42(3):546-8. DOI: 10.1023/a:1018895009305. View

Harrison S, Torgerson S, Hayashi P . The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol. 2003; 98(9):2042-7. DOI: 10.1111/j.1572-0241.2003.07659.x. View

10.

Adams L, Sanderson S, Lindor K, Angulo P . The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol. 2005; 42(1):132-8. DOI: 10.1016/j.jhep.2004.09.012. View

11.

Sasso M, Beaugrand M, de Ledinghen V, Douvin C, Marcellin P, Poupon R . Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010; 36(11):1825-35. DOI: 10.1016/j.ultrasmedbio.2010.07.005. View

12.

Rockey D, Caldwell S, Goodman Z, Nelson R, Smith A . Liver biopsy. Hepatology. 2009; 49(3):1017-44. DOI: 10.1002/hep.22742. View

13.

Nagaya T, Yoshida H, Takahashi H, Matsuda Y, Kawai M . Body mass index (weight/height2) or percentage body fat by bioelectrical impedance analysis: which variable better reflects serum lipid profile?. Int J Obes Relat Metab Disord. 1999; 23(7):771-4. DOI: 10.1038/sj.ijo.0800961. View

14.

Foster K, Dewbury K, Griffith A, Wright R . The accuracy of ultrasound in the detection of fatty infiltration of the liver. Br J Radiol. 1980; 53(629):440-2. DOI: 10.1259/0007-1285-53-629-440. View

15.

Chon C, Kim B, Cho Y, Sung K, Bae J, Kim T . Effect of nonalcoholic Fatty liver disease on the development of type 2 diabetes in nonobese, nondiabetic korean men. Gut Liver. 2012; 6(3):368-73. PMC: 3404176. DOI: 10.5009/gnl.2012.6.3.368. View

16.

Hepburn M, Vos J, Fillman E, Lawitz E . The accuracy of the report of hepatic steatosis on ultrasonography in patients infected with hepatitis C in a clinical setting: a retrospective observational study. BMC Gastroenterol. 2005; 5:14. PMC: 1087838. DOI: 10.1186/1471-230X-5-14. View

17.

Myers R, Fong A, Shaheen A . Utilization rates, complications and costs of percutaneous liver biopsy: a population-based study including 4275 biopsies. Liver Int. 2008; 28(5):705-12. DOI: 10.1111/j.1478-3231.2008.01691.x. View

18.

de Ledinghen V, Vergniol J, Foucher J, Merrouche W, Le Bail B . Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int. 2012; 32(6):911-8. DOI: 10.1111/j.1478-3231.2012.02820.x. View

19.

Dasarathy S, Dasarathy J, Khiyami A, Joseph R, Lopez R, McCullough A . Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol. 2009; 51(6):1061-7. PMC: 6136148. DOI: 10.1016/j.jhep.2009.09.001. View

20.

Kim H, Kim D, Huh K . Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome. Atherosclerosis. 2008; 204(2):521-5. DOI: 10.1016/j.atherosclerosis.2008.09.012. View